Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Will 2023 see a resurgence of traditional public M&A deals or will macro factors and the looming threat of regulatory review continue to push biotechnology companies down creative paths? It’s a more challenging market environment right now than we’ve seen in many years,” said Charlie Kim , who co-chairs Cooley’s capital markets practice.
40 
Let's personalize your content